Nazione: Malta
Lingua: inglese
Fonte: Medicines Authority
CYTARABINE
1 A Pharma GmbH Keltenring 1+3, 82041 Oberhaching, Germany
L01BC01
CYTARABINE 50 mg/ml
SOLUTION FOR INJECTION
CYTARABINE 50 mg/ml
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2007-01-29
PACKAGE LEAFLET ALEXAN, INJECTION LIQUID 50 MG/ML READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours. IN THIS LEAFLET: 1. What Alexan is and what it is used for 2. Before you take Alexan 3. How to take use Alexan 4. Possible side effects 5. 5 Storing Alexan 6. Further information The vials contain either • 500mg Alexan (Cytarabine) in 10ml • 1000mg Alexan (Cytarabine) in 20ml • 2000mg Alexan (Cytarabine) in 40ml • The active substance is Cytarabine • The other ingredients are sodium lactate, lactic acid and water for injections Marketing Authorisation Holder: 1 A Pharma GmbH, Keltenring 1+3, 82041 Oberhaching, Germany Manufacturer: Ebewe Pharma Ges.m.b.H. Nfg. KG A-4866 Unterach, Austria 1. WHAT ALEXAN IS AND WHAT IT IS USED FOR The drug Alexan is used to treat cancer. It can be used alone but more commonly it is used in combination with other anti-cancer agents. Alexan can be used as monotherapy or in combination with other chemotherapeutics in adults and children with: • Acute myeloid leukaemia (AML) • Acute lymphoblastic leukaemia (ALL) • Chronic myeloid leukaemia (CML) • Intermediate non-Hodgkin’s lymphomas and high malignancy non-Hodgkin’s lymphomas (such as lymphoblastic non-Hodgkin’s lymphomas and Burkitt- type non-Hodgkin’s lymphomas). • Prophylaxis and treatment of leukaemia in the central nervous system: Alexan can be administered intrathecally in combination with methotrex Leggi il documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE DRUG Alexan, Solution for injection 50 mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 50.0 mg Cytarabine For a full list of excipients, see 6.1. 3. PHARMACEUTICAL FORM Solution for injection The solution is a clear and colourless solution 4. CLINICAL DATA 4.1. THERAPEUTIC INDICATIONS Cytarabine can be used as monotherapy or in combination with other chemotherapeutics in adults and children with: - Acute myeloid leukaemia (AML) - Acute lymphoblastic leukaemia (ALL) - Chronic myeloid leukaemia (CML) - Intermediate non-Hodgkin’s lymphomas and high malignancy non-Hodgkin’s lymphomas (such as lymphoblastic non-Hodgkin’s lymphomas and Burkitt- type non-Hodgkin’s lymphomas). - Prophylaxis and treatment of leukaemia in the central nervous system: cytarabine can be administered intrathecally in combination with methotrexate and corticosteroids. 4.2. DOSAGE AND METHOD OF ADMINISTRATION Cytarabine must only be administered in specialised clinics, by doctors with extensive experience of chemotherapy, and who can offer sufficient opportunities for supportive treatment. Cytarabine is inactive orally. The dosage and administration method are dependent on the treatment schedule to be followed. Before commencing chemotherapy, the doctor must be aware of the professional literature in the matter, unwelcome side effects, precautionary measures, contra-indications and warnings in the context of the drugs included in the therapy programme. Cytarabine can be administered as a single drug or in combination with other cytotoxic drugs, or occasionally corticosteroids. It is only possible to give general recommendations, as leukaemia is often treated with combinations of cytotoxic drug Leggi il documento completo